These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 2412053)
41. Is there alpha-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment? Ball SG; Robertson JI J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S120-2. PubMed ID: 2412031 [TBL] [Abstract][Full Text] [Related]
42. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs. van de Water A; Wouters L; Xhonneux R; Reneman S Arch Int Pharmacodyn Ther; 1985 Jun; 275(2):267-78. PubMed ID: 3161481 [TBL] [Abstract][Full Text] [Related]
43. The influence of ketanserin on hemostasis in vitro. Bergqvist D; Arvidsson S; Haglund U; Hedner U; Lindblad B Thromb Res; 1986 Jul; 43(2):237-41. PubMed ID: 2943051 [TBL] [Abstract][Full Text] [Related]
44. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension. Stott DJ; Saniabadi AR; Hosie J; Lowe GD; Ball SG Eur J Clin Pharmacol; 1988; 35(2):123-9. PubMed ID: 3142775 [TBL] [Abstract][Full Text] [Related]
45. Ketanserin in the acute management of severe hypertension. Murphy BF; Whitworth JA; Kincaid-Smith P J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S168-71. PubMed ID: 2412044 [TBL] [Abstract][Full Text] [Related]
47. Continuous inhibition of the platelet S2-serotonergic receptors during the long term administration of ketanserin. Vermylen J; Arnout J; Deckmyn H; Xhonneux B; De Clerck F Thromb Res; 1986 Jun; 42(5):721-3. PubMed ID: 2940729 [No Abstract] [Full Text] [Related]
48. Ketanserin: a possible tool for studying the role of serotonin in hypertension. Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035 [TBL] [Abstract][Full Text] [Related]
49. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects. Gasic S; Eichler HG; Korn A J Cardiovasc Pharmacol; 1985; 7(2):219-23. PubMed ID: 2581071 [TBL] [Abstract][Full Text] [Related]
50. Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit. Bolt GR; Saxena PR Hypertension; 1985; 7(4):499-506. PubMed ID: 2861161 [TBL] [Abstract][Full Text] [Related]
51. Comparative effects of ketanserin, a novel serotonergic receptor antagonist, on 5HT-induced shape change and 5HT uptake in rat and human platelets. Lampugnani MG; de Gaetano G Biochem Pharmacol; 1982 Sep; 31(18):3000-2. PubMed ID: 7138588 [No Abstract] [Full Text] [Related]
52. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study. Arneklo-Nobin B; Elmér O; Akesson A Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356 [TBL] [Abstract][Full Text] [Related]
53. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278 [TBL] [Abstract][Full Text] [Related]
59. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685 [TBL] [Abstract][Full Text] [Related]
60. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension. Hedner T; Persson B Am J Hypertens; 1988 Jul; 1(3 Pt 3):317S-323S. PubMed ID: 3046635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]